Bifemelane – (90293-01-9)

Bifemelane is an antidepressant and cerebral activator used in the treatment of cerebral infarction patients with depressive symptoms and dementia. It also shows potential in treating glaucoma.

Bifemelane acts as a monoamine oxidase inhibitor (MAOI) for both MAO-A and MAO-B, with reversible inhibition of MAO-A and non-competitive irreversible inhibition of MAO-B. It also weakly inhibits norepinephrine reuptake.

The drug has nootropic, neuroprotective, and antidepressant-like effects in animal models and enhances the cholinergic system in the brain.

The above informationis displayed for information purpose only, and has not been reviewed by EON nor does EON attests or validates the accuracy nor does it constitutes a recommendation or validation.

Sources:

https://en.wikipedia.org/wiki/Bifemelane
https://pubchem.ncbi.nlm.nih.gov/compound/2377
https://www.medchemexpress.com/bifemelane.html
https://www.medkoo.com/products/11301
https://www.sciencedirect.com/science/article/pii/S1347861319345244
https://synapse.patsnap.com/article/what-is-the-mechanism-of-bifemelane-hydrochloride